drugset / Trial / NCT00771602
Alemtuzumab + Rituximab Consolidation in CLL
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find out how well Campath (alemtuzumab), Rituxan (rituximab), or a combination of the 2 drugs may control Chronic Lymphocytic Leukemia (CLL) that is left after chemotherapy. The safety of these drugs will also be studied.
Timeline
- Start
- 2008-08
- Primary completion
- 2010-12
- Completion
- 2010-12
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |